Validation to velocity: Japan’s pharma model comes under execution pressure
Validation to velocity: Japan’s pharma model comes under execution pressure
Publish Date: 2026-05-28 05:06:00
Source Domain: www.pharmaceutical-technology.com
Japan’s pharmaceutical market is the third largest in the world, following the United States and China. Credit: Vitalii Stock via Shutterstock.com.
Japan’s pharmaceutical industry – the world’s third largest by market value after the United States and China – has long been associated with methodical development cycles and rigorous technical validation. But the sector is undergoing a gradual yet increasingly visible shift in how it evaluates external partners and drug development programmes.
Across therapeutics, particularly complex modalities such as peptides, the defining constraint is moving from scientific feasibility to execution speed.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Find out more
“The ‘how?’ has given way to the ‘how soon?’” explained Sharadsrikar Kotturi, chief scientific officer at Indian contract development and manufacturing organisation (CDMO) Neuland Laboratories, describing what he sees as a structural change in Japan’s engagement with global pharmaceutical partners.
Kotturi said the change was particularly visible at this year’s CPHI Japan forum, where conversations shifted from technical exploration to timelines, scalability and execution certainty. The evolving atmosphere was reflected even in the dress code, with ties and polished leather shoes increasingly replaced by sneakers and more casual attire – a visible sign of Japan’s…
